Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06948981 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 6 words
    • Site details revised
    • Collaborators: details revised at 1 of 1 entry
  2. Primary endpoint revisedv2 Show 5 more changesShow less
    • Enrollment target: 34 to 46
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study site revised
    • Collaborators expanded, about 8 words
    • Study title revised
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Grit Biotechnology
30 trials monitored
See 1 trial at risk
Leukemia
2,948 trials monitored
See 180 trials at risk
This study is a prospective single-arm open-labled phase I/II clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in relapsed/refractory CD19 positive adult B-cell non Hodgkin lymphoma (B-NHL) and B-acute lymphoblastic leukemia (B-ALL) patients. A total of 46 subjects (anticipated) will be enrolled in this study.
Trial Details
NCT Number NCT06948981
Lead Sponsor Grit Biotechnology
Collaborators: Institute of Hematology & Blood Diseases Hospital, China
Conditions
(from sponsor)		 Hematological Malignancy (Leukemia- Lymphoma)
Related terms Hematologic Neoplasms
Enrollment 46 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov